Clinical Trial Update: Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating serplulimab plus chemotherapy as neoadjuvant and adjuvant therapy for resectable non-small cell lung cancer has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Fudan University | Conditions: Non-small Cell Lung Cancer, Stage II-IIIA | Phase 2 | Status: COMPLETED